Janssen
Janssen Seeking European Approval for Carvykti as Earlier Refractory Multiple Myeloma Treatment
The firm submitted data from CARTITUDE-4, which showed the CAR T-cell therapy improved patients' progression-free survival compared to standard-of-care regimens.
Nexcella CAR T-Cell Therapy Amyloidosis Trial Yields Promising Safety, Efficacy Data
At ASGCT's annual meeting, researchers shared data suggesting that the autologous cell therapy could benefit patients with the rare, multiple myeloma-associated disease.
While patients can benefit greatly from non-trial access to investigational therapies, policy experts are calling for more guardrails around those programs.
Janssen, Cellular Biomedicine Group Sign Deal to Develop CAR T-Cell Therapies
The deal gives Janssen exclusive worldwide rights to CBMG's CD20-directed autologous CAR T-cell therapies, except in greater China.
J&J Reports 4 Percent Growth in Cancer Drug Revenue; Breaks Out Carvykti Sales
The firm for the first time reported sales of its BCMA-directed CAR T-cell therapy, which brought in $72 million in the first quarter of 2023.